Some of Januvia generics acquire ‘exclusive sales right’
Some of pharmaceutical companies owning generics of antidiabetic Januvia(sitagliptin), a DPP-4 inhibitor, acquired the exclusive sale right. They are sitagliptin single products, sitagliptin-metformin complexes and sitagliptin-metformin release-type products.
The ‘exclusive sale right’ will be o...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
